From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs
New CPT review by Certara's Karen Rowland Yeo & Piet van der Graaf shows how…
Danielle Pillsbury2026 年 9 月 23 日
Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape
2026 年 10 月 29 日 - 11:00 PM – 2:00 PM
Chara Litou2026 年 9 月 9 日
Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape
2026 年 9 月 30 日 - 11:30 PM – 2:00 PM
Certara2026 年 8 月 12 日
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data
QSP modeling reveals patient-specific factors driving CAR T-cell response and relapse in multiple myeloma, with…
Certara2026 年 7 月 20 日
Expert Q&A: Identify Winning Biotherapeutics in Early Discovery
Watch this on-demand Q&A on using mechanistic modeling to assess feasibility and prioritize biotherapeutic candidates…
Certara2026 年 7 月 17 日
Integrated mechanistic modeling approaches in oncology drug development
Learn how integrated QSP and PBPK modeling supports dose justification, patient stratification, and regulatory decisions…
Certara2026 年 7 月 8 日
Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment
This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…
Certara2026 年 6 月 2 日
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…
Certara2026 年 5 月 26 日
Advancing In Vivo CAR-T with QSP
Learn how QSP modeling improves first-in-human dose selection for CAR-T therapies, enabling better translation and…
Certara2026 年 5 月 12 日
Certara IQ™ Demo
Watch a short demo of Certara IQ™, a QSP platform for modeling, simulation, and analysis.…
Certara2026 年 5 月 12 日
